Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Murphy Oil swings to Q3 net profit attributable to Murphy of $171.12 million year-on-year

Murphy Oil swings to Q3 net profit attributable to Murphy of $171.12 million year-on-year

BitgetBitget2026/11/04 22:34
  • Murphy Oil swung to third-quarter 2026 net income attributable to shareholders of $171.12 million from a year-earlier loss.
  • Revenue from production rose 18% year over year to $849.18 million.
  • Quarterly production fell 7% year over year to 186,495 barrels of oil equivalent per day, exceeding guidance.
  • First oil flowed from the Lac Da Vang development offshore Vietnam less than three years after project sanction.
  • Full-year 2026 production guidance increased to 176,000–178,000 barrels of oil equivalent per day.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Murphy Oil Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104467052) on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss